Spondyloarthritis & psoriatic arthritis
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry
Authors' conclusion
IXE effectiveness was highlighted after 6 months at both joint and skin levels and lasted up to 24 months in different clinical scenarios
Study context
- Population
- Moderate-severe psoriatic arthritis (PsA) outpatients treated with ixekizumab (IXE) in the Italian Gruppo Italiano Studio Early Arthritis (GISEA) registry, January 2019-June 2023
- Participants
- 223 PsA outpatients
- Outcome
- IXE effectiveness (TJC, SJC, VAS-pain, DAPSA)
- Follow-up
- 6, 12 and 24 months
Methodological detailsmulticentre, real-life observational, registry-based (GISEA), Data collected at baseline and every six months
- Multicentre
- Real-life observational
- Registry-based (GISEA)
- Data collected at baseline and every six months
Main finding
As reported in the abstract
Effectiveness of IXE · T6, T12, T24
Disease Activity in PSoriatic Arthritis (DAPSA) remission at T12
22%
DAPSA remission at T24
18.5%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Predictor of treatment response (multivariate analysis): male sex · T6Malevs FemaleLost significance at T12 | 2.49 (1.11–5.54) | P = 0.02 | |
| 0.20.5125Odds ratio (log scale) |
Sex differences in response · T6 and T12
- Males had higher DAPSA and Visual Analogue Scale (VAS)-pain reduction, higher percentage in DAPSA remission/LDA at T6, and higher ∆Psoriasis Area Severity Index (PASI) at T6 and T12 than females
- Baseline: higher FM and csDMARD combination therapy in females; higher PASI in males
Original publication
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry. Clin Exp Rheumatol. Published 24 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →